Overall rank by patents
#8,138
of 50,000 tracked assignees
USPTO PatentsView assignee record - 40 granted patents across 10 technology areas, recorded in grant years 2015–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61M (DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY ; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY ; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR).
The verdict
According to USPTO PatentsView, Unomedical ranks #8,138 of 50,000 tracked US assignees by granted-patent volume, with 40 patents across 10 technology areas.
Unomedical A/s has been granted 40 US utility patents between 2015 and 2025, placing Unomedical A/s at #8,138 of 50,000 across all assignees tracked by PlainPatent. This portfolio spans 10 distinct Cooperative Patent Classification (CPC) subclasses, averaging 15.8 claims per patent with primary concentration in A61M (DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY ; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY ; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR). As a Foreign Corporation, Unomedical A/s is one of the more focused assignees in the PatentsView dataset. By volume, Unomedical sits between Uhlmann Pac-systeme Gmbh & Co. KG (40 patents, rank #8,132) and Vector Products, Inc. (40 patents, rank #8,140) - the closest US assignees by grant volume. The composite Innovation Score of 40.8/100 blends portfolio volume, grant velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.
Grant cadence records the difference between two grant-year windows. Between 2020 and 2024 the company received 20 grants, compared with 18 in the 2015–2019 window, a +11% shift in five-year grant velocity. Both windows cover five complete grant years; the latest PatentsView year is a partial release and is excluded from this comparison, though it still appears in the yearly table and chart below. Grant timing can lag the related application by years, so this comparison does not establish current R&D spending, strategic intent, or a company’s application activity. The Foreign Corporation classification provides context for the assignee record, not a conclusion about its business strategy.
Claim depth and technology breadth describe this aggregate record. Unomedical A/s's 15.8 average claims per patent is an average count, not a measure of claim scope, legal strength, enforceability, or design-around risk. The record spans 10 CPC subclasses. Combined with portfolio volume, these figures let readers compare the documented grant records of assignees in similar technology classes.
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
UHLMANN PAC-SYSTEME GMBH & CO. KG
40 patents
UNIVERSITAT AUTÓNOMA DE BARCELONA
40 patents
UNIVERSITY OF MISSISSIPPI
40 patents
Universite de Versailles Saint-Quentin-en-Yvelines
40 patents
VACON OY
40 patents
VELO3D, INC.
40 patents
Vasona Networks, Inc.
40 patents
Vector Products, Inc.
40 patents
Unomedical A/S
40 patents
What this shows Unomedical holds 40 patents at rank #8,136, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
By rank, the assignees closest to #8,136 in granted patent volume.
Other assignees with the most granted patents in Unomedical's primary technology class.
Unomedical's Innovation Score vs. every tracked assignee
Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)
41 Top 35% higher than 65% of 50,000 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2015 | 5 | 12.5% |
| 2016 | 5 | 12.5% |
| 2017 | 3 | 7.5% |
| 2018 | 2 | 5.0% |
| 2019 | 3 | 7.5% |
| 2020 | 3 | 7.5% |
| 2021 | 5 | 12.5% |
| 2022 | 3 | 7.5% |
| 2023 | 4 | 10.0% |
| 2024 | 5 | 12.5% |
| 2025partial year | 2 | 5.0% |
Top 10 of 10 technology areas
Historical grant data only; it does not rate legal strength or current strategy.
Overall rank by patents
#8,138
of 50,000 tracked assignees
40.8 out of 100
How to use this portfolio
Unomedical's 40 grants land it in the top 35% by Innovation Score, but volume alone doesn't tell you where the strength sits.
Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.